FOLD Share Price

Open 15.63 Change Price %
High 15.70 1 Day -1.17 -7.41
Low 14.59 1 Week 0.73 5.26
Close 14.61 1 Month 1.97 15.59
Volume 4264343 1 Year 6.98 91.48
52 Week High 16.06
52 Week Low 4.41
FOLD Important Levels
Resistance 2 15.64
Resistance 1 15.21
Pivot 14.97
Support 1 14.01
Support 2 13.58
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
NETE 0.72 44.00%
SCHS 0.04 33.33%
MRGE 0.55 30.95%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PGRX 0.05 25.00%
ESMC 0.12 20.00%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
CAFI 0.00 -100.00%
ORIG 24.00 -96.52%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

FOLD Technical Analysis 4
As on 22nd Sep 2017 FOLD Share Price closed @ 14.61 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.58 & Buy for SHORT-TERM with Stoploss of 13.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
FOLD Target for September
1st Target up-side 15.47
2nd Target up-side 16.54
3rd Target up-side 17.61
1st Target down-side 12.41
2nd Target down-side 11.34
3rd Target down-side 10.27
FOLD Other Details
Segment EQ
Market Capital 229448784.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.amicustherapeutics.com
FOLD Address
FOLD
1 Cedar Brook Drive
Cranbury, NJ 08512
United States
Phone: 609-662-2000
Fax: 609-662-2001
FOLD Latest News
Interactive Technical Analysis Chart Amicus Therapeutics, Inc. ( FOLD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amicus Therapeutics, Inc.
FOLD Business Profile
Amicus Therapeutics, Inc. (Amicus) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration. It is focused on the development of pharmacological chaperone monotherapy programs and pharmacological chaperones in combination with enzyme replacement therapy (ERT). Its approach to the treatment of human genetic diseases consists of using pharmacological chaperones that selectively bind to the target protein. Amicus is also conducting preclinical studies on the use of its pharmacological chaperone technology to treat Parkinson�s disease, with an initial focus on Parkinson�s disease patients who are also Gaucher disease carriers.